BRAF mutations in patients with non-small cell lung cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Chen, Dong ^a   Zhang, Li Qun ^a   Huang, Jun Fu ^a   Liu, Kai ^a   Chuai, Zheng Ran ^a   Yang, Zhao ^a   Wang, Yun Xia ^a   Shi, Da Chuan ^a   Liu, Qian ^a   Huang, Qing ^a   Fu, Wei Ling ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; EFFECT SIZE; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; META ANALYSIS; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; TUMOR GENE; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MISSENSE MUTATION; NON SMALL CELL LUNG CANCER;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84903585828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101354     Document Type: Article

References (32)

1. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
2. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18: 1059-1068.
3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
4. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
5. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, et al. (2013) Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res 19: 4532-4540.
6. Clinical, Lung Cancer Genome Project CLCGP, and Genomic Medicine NGM Network (2013) A genomics-based classification of human lung tumors. Sci Transl. Med 209: 209ra153.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
8. Pendharkar D, Ausekar BV, Gupta S (2013) Molecular Biology of Lung Cancer-A Review. Indian J Surg Oncol 4: 120-124.
9. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. (2012) Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib. N Engl J Med 366: 707-714.
10. Tol J, Nagtegaal ID, Punt CJA (2009) BRAF Mutation in Metastatic Colorectal Cancer. N Engl J Med 361: 98-99.
11. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262.
12. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, et al. (2012) The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer 118: 1764-1773.
13. Mao C, Qiu L-X, Liao R-Y, Du F-B, Ding H, et al. (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 69: 272-278.
14. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, et al. (2009) EGFR/KRAS/ BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-4560.
15. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, et al. (2010) Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 5: 1734-1740.
16. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, et al. (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29: 3574-3579.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
19. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, et al. (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68: 9375-9383.
20. Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, et al. (2011) Clinical Significance of BRAF Gene Mutations in Patients with Non-small Cell Lung Cancer. Anticancer Res 31: 4619-4623.
21. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, et al. (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046-2051.
22. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, et al. (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7: e40109.
23. Sasaki H, Shitara M, Yokota K, Okuda K, Hikosaka Y, et al. (2012) Braf and erbB2 mutations correlate with smoking status in lung cancer patients. Exp Ther Med 3: 771-775.
24. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, et al. (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24: 742-748.
25. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci 105: 3041-3046.
26. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis. PLos One 7: e47054.
27. Li C, Lee KC, Schneider EB, Zeiger MA (2012) BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a metaanalysis. J Clin Endocrinol Metab 97: 4559-4570.
28. Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164: 776-784.
29. Kalady MF, DeJulius KL, Sanchez JA, Jarrar A, Liu X, et al. (2012) BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55: 128-133.
30. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
31. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, et al. (2011) Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 128: 2075-2084.
32. Sclafani F, Gullo G, Sheahan K, Crown J (2013) BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol 87: 55-68.